Results 21 to 30 of about 775,328 (297)

Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease.

Cancer Discovery, 2021
Growing evidence demonstrates that circulating tumor DNA (ctDNA) minimal residual disease (MRD) following treatment for solid tumors predicts relapse.
E. Moding, B. Nabet, Ash A. Alizadeh, M. Diehn   +3 more
semanticscholar   +1 more source

Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA

Nature Biotechnology, 2021
Circulating tumor-derived DNA (ctDNA) is an emerging biomarker for many cancers, but the limited sensitivity of current detection methods reduces its utility for diagnosing minimal residual disease.
D. Kurtz, Joanne Soo, Lyron Co Ting Keh, S. Alig, J. Chabon, B. Sworder, A. Schultz, M. Jin, F. Scherer, A. Garofalo, C. Macaulay, Emily G. Hamilton, Binbin Chen, M. Olsen, J. Schroers-Martin, A. Craig, E. Moding, M. S. Esfahani, C. Liu, U. Dührsen, A. Hüttmann, R. Casasnovas, J. Westin, M. Roschewski, W. Wilson, G. Gaidano, D. Rossi, M. Diehn, Ash A. Alizadeh   +28 more
semanticscholar   +1 more source

Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors [PDF]

, 2002
FLT3 mutations, either internal tandem duplications (ITDs) or aspartate residue 835 (D835) point mutations, are present in approximately one third of patients with acute myeloid leukemia (AML) and have been associated with an increased relapse rate.
Bowen, D.T., Frew, M.E., Gale, R.E., Kottaridis, P.D., Langabeer, S.E., Linch, D.C.   +5 more
core   +1 more source

Re: Molecular testing to deliver personalised chemotherapy recommendations

BMC Medicine, 2023
Background There is an increasing focus over time on the discovery and validation of biomarkers in cancer medicine, which can inform the identification of patients that are most likely to benefit from treatment, which therapy is most likely to be ...
Peter Gibbs, Wei Hong, Jeanne Tie
doaj   +1 more source

Minimal residual disease in EGFR-mutant non-small-cell lung cancer

Frontiers in Oncology, 2022
Targeted therapy with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) is an effective treatment for EGFR-mutant non-small-cell lung cancer (NSCLC), however most patients invariably relapse after a period of minimal residual ...
Nathan T. Bain, Yang Wang, Surein Arulananda, Surein Arulananda, Surein Arulananda, Surein Arulananda   +5 more
doaj   +1 more source

Minimal Residual Disease [PDF]

Leukemia Supplements, 2003
The aim of minimal residual disease (MRD) studies in patients with acute leukemia is to measure initial treatment response accurately, provide an assessment of the residual leukemic burden throughout therapy and detect relapse early. Therefore, information resulting from MRD monitoring can substantially improve many facets of clinical management ...
openaire   +2 more sources

Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study

Journal of Clinical Oncology, 2021
PURPOSE CAPTIVATE (NCT02910583), a randomized phase II study, evaluates minimal residual disease (MRD)-guided treatment discontinuation following completion of first-line ibrutinib plus venetoclax treatment in patients with chronic lymphocytic leukemia ...
W. Wierda, J. Allan, T. Siddiqi, T. Kipps, Stephen Samuel Opat, A. Tedeschi, X. Badoux, B. Kuss, S. Jackson, C. Moreno, R. Jacobs, J. Pagel, I. Flinn, Y. Pak, Cathy Zhou, E. Szafer-Glusman, J. Ninomoto, J. Dean, D. James, P. Ghia, C. Tam   +20 more
semanticscholar   +1 more source

Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study

Journal of Clinical Oncology, 2021
PURPOSE The CLL14 study has established one-year fixed-duration treatment of venetoclax and obinutuzumab (Ven-Obi) for patients with previously untreated chronic lymphocytic leukemia.
O. Al-Sawaf, Can Zhang, T. Lu, Michael Z. Liao, A. Panchal, S. Robrecht, T. Ching, M. Tandon, A. Fink, E. Tausch, C. Schneider, M. Ritgen, S. Böttcher, K. Kreuzer, B. Chyla, D. Miles, C. Wendtner, B. Eichhorst, S. Stilgenbauer, Yanwen Jiang, M. Hallek, K. Fischer   +21 more
semanticscholar   +1 more source

A systematic literature review and meta-analysis of minimal residual disease as a prognostic indicator in adult B-cell acute lymphoblastic leukemia

Haematologica, 2019
Minimal (or ‘measurable’) residual disease in acute lymphoblastic leukemia appears to be a prognostic indicator, with potential value in informing individualized treatment decisions.
Renato Bassan, Monika Brüggemann, Hoi-Shen Radcliffe, Elizabeth Hartfield, Georg Kreuzbauer, Sally Wetten   +5 more
doaj   +1 more source

Comparative analysis of Ig and TCR gene rearrangements at diagnosis and at elapse of childhood precursor-B–ALL provides improved strategies for selection of stable PCR targets for monitoring of minimal residual disease [PDF]

, 2002
Immunoglobulin (Ig) and T-cell receptor (TCR) gene rearrangements are excellent patient-specific polymerase chain reaction (PCR) targets for detection of minimal residual disease (MRD) in acute lymphoblastic leukemia (ALL), but they might be unstable ...
Brinkhof, B. (Bas), Burg, M. (Mirjam) van der, Dongen, J.J.M. (Jacques) van, Szczepanski, T. (Tomasz), Wering, E.R. (Elisabeth) van, Willemse, M.J.   +5 more
core   +3 more sources